Is Buying Enanta Pharmaceuticals Inc (ENTA) Here a Winning Strategy?

September 17, 2017 - By Nellie Frank

Investors sentiment decreased to 1.47 in 2016 Q4. Its down 0.06, from 1.53 in 2016Q3. It worsened, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported.
28,400 are held by Virginia Retirement Systems Et Al. Arizona State Retirement stated it has 7,200 shares. Acadian Asset Mngmt Limited Com holds 0.09% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 568,686 shares. Walleye Trading Ltd holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 9,500 shares. Alphamark Advsr Ltd Liability Corp accumulated 33,000 shares. Ameriprise Fincl holds 113,535 shares or 0% of its portfolio. Da Davidson Co has 1,735 shares. Alliancebernstein Ltd Partnership reported 132,060 shares. Shell Asset Co, Netherlands-based fund reported 15,946 shares. State Of Alaska Department Of Revenue stated it has 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Fmr Ltd Llc has 391,815 shares for 0% of their portfolio. Seizert Capital Ltd Liability Co has invested 0.18% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Us Comml Bank De, a Minnesota-based fund reported 2,224 shares. Great Point Prns Ltd Liability Company holds 5.7% or 828,253 shares in its portfolio. Teachers Retirement Of The State Of Kentucky stated it has 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock increased 4.55% or $1.96 on September 15, reaching $45.06. About 355,589 shares traded or 88.35% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since September 17, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.
The move comes after 8 months positive chart setup for the $860.21 million company. It was reported on Sep, 17 by Barchart.com. We have $48.66 PT which if reached, will make NASDAQ:ENTA worth $68.82 million more.

Analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report $1.94 EPS on November, 20.They anticipate $2.03 EPS change or 2,255.56 % from last quarter’s $-0.09 EPS. ENTA’s profit would be $37.04 million giving it 5.81 P/E if the $1.94 EPS is correct. After having $-0.44 EPS previously, Enanta Pharmaceuticals Inc’s analysts see -540.91 % EPS growth.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 14 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Zacks on Friday, August 7 to “Buy”. As per Tuesday, July 11, the company rating was upgraded by JMP Securities. The company was maintained on Tuesday, August 8 by Robert W. Baird. JP Morgan maintained the stock with “Overweight” rating in Tuesday, August 9 report. JMP Securities downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Thursday, April 28 to “Market Perform” rating. JMP Securities upgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Friday, October 23 to “Mkt Outperform” rating. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Buy” rating given on Saturday, August 8 by TheStreet. As per Friday, October 23, the company rating was downgraded by Barclays Capital.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta Pharmaceuticals: Updates To Thesis” on August 06, 2017, also Seekingalpha.com with their article: “Enanta: Half Cash, All Upside” published on February 28, 2017, Seekingalpha.com published: “Biotech Forum Daily Digest: Fallout From The ACA Repeal Debacle. Spotlight On …” on March 27, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta To Retain Momentum On The Back Of Upcoming FDA Decision” published on July 10, 2017 as well as Businesswire.com‘s news article titled: “Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its …” with publication date: September 13, 2017.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $860.21 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.